Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy
Jennifer L. Crombie(Dana-Farber Cancer Institute), Brian Hess(Washington University in St. Louis), Jordan Gauthier(Seattle Cancer Care Alliance), Geoffrey Shouse(City Of Hope National Medical Center), Robert Redd(Harvard University), Erin Mullane(University of Washington), Alex F. Herrera(City of Hope), Roch Houot(Inserm), Jonathon B. Cohen(Emory University), Kirk E. Cahill(University of Chicago), Caron A. Jacobson(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Anna Saucier(Dana-Farber Cancer Institute), Jason T. Romancik(Emory University), Victor A. Chow(Whipps Cross University Hospital), Justin Kline(University of Chicago)
Cited by 6
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|595
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
|Journal of Clinical Oncology|2017|468